keyboard_arrow_up

Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations


GBI Research, a leading business intelligence provider, has released its latest research report,"Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from 18.4 billion in 2013 to a projected value of 21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.

The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.

Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.

View Complete Report With TOC at:-  https://marketreportscenter.com/reports/5228/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations


Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.

Scope

The report covers and includes - 
- An introduction to asthma, including discussion of disease epidemiology, etiology pathophysiology, symptoms, diagnosis, and treatment, with clinical data for drugs featured in the current treatment algorithm discussed in detail
- In-depth analysis of the current marketed products landscape, including product profiles of the main drugs used and heat maps that compare their safety and efficacy parameters
- Comprehensive analysis of the asthma pipeline by phase of development, molecule type, and molecular target and novelty, and comparative analysis of the most promising late-stage pipeline drugs, as well as heat maps and a competitor matrix that compares safety and efficacy parameters
- Additional in-depth analysis of the asthma clinical trials landscape, including trends in size, duration and failure rate
- Forecast projections for the asthma market to 2020, including analysis of the global market and each of the eight major markets and incorporating projected, low, and high-variance scenarios based on treatment usage patterns and annual cost of therapy in each of the major markets
- Discussion of the strategic consolidations landscape, including trends in co-development and licensing deals relevant to asthma drug products

Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches by allowing them to - 
- Gain a comprehensive understanding of asthma, including diagnosis, disease severity, and treatment algorithms
- Understand the current asthma marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved
- Identify trends, developments, and prominent molecule types and molecular targets within the asthma pipeline
- Gain an appreciation of the clinical and commercial aspects of the most promising late-stage pipeline molecules and their potential competitive impact on the future market
- Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration and failure rate, phase of development, molecule type, and molecular target
- Observe projections for treatment usage patterns, annual therapy costs, and market growth in the eight major markets and understand reasons for variance in projected patterns of growth

Download Sample at:- https://marketreportscenter.com/request-sample/5228

Table of Content

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Etiology 11
2.4 Pathophysiology 12
2.5 Symptoms 12
2.6 Diagnosis 12
2.7 Assessment of Disease Severity 13
2.8 Treatment 15
2.9 Treatment Algorithm 16
2.10 Treatment Segments 18
2.10.1 ICS Monotherapy for the Maintenance Treatment of Asthma 19
2.10.2 Singulair (montelukast sodium) as First-Line Maintenance Therapy 21
2.10.3 ICS/LABA Combination Therapy 22
2.10.4 Add-on Therapies 27
3 Marketed Products 33
3.1 Overview 33
3.2 ICS for the Maintenance Treatment of Asthma 33
3.2.1 Arnuity (fluticasone furoate) - GSK 33
3.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma 34
3.3.1 Advair (fluticasone propionate and salmeterol xinafoate) - GSK 34
3.3.2 Symbicort (budesonide and formoterol fumarate) - AstraZeneca, Co-Promotion with Astellas Pharma 35
3.3.3 Dulera (mometasone furoate and formoterol fumarate) - Merck 36
3.3.4 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) - GlaxoSmithKline/Theravance 37
3.4 Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma 38
3.4.1 Xolair (omalizumab) - Novartis and Genentech 38
3.4.2 Singulair (montelukast) - Merck 39
3.4.3 Spiriva (tiotropium bromide) - Boehringer Ingelheim 40
3.5 Heat Maps for Marketed Products 42
4 Asthma Pipeline 44
4.1 Overview 44
4.2 Pipeline Analysis by Stage of Development, Molecule Type and Program Type 44
4.3 Pipeline Analysis by Molecular Target 46
4.4 Asthma Clinical Trial Landscape 53
4.4.1 Clinical Trial Failure Rates 53
4.4.2 Clinical Trial Duration 58
4.4.3 Clinical Trial Size 62
4.4.4 Comparative Clinical Trial Metrics Analysis 69
4.5 Promising Pipeline Molecules 71
4.5.1 Mepolizumab - GSK 71
4.5.2 Reslizumab - Teva Pharmaceutical 73
4.5.3 Lebrikizumab - Roche/Genentech 75
4.5.4 Dupilumab - Regeneron Pharmaceuticals in Collaboration with Sanofi 77
4.5.5 Masitinib - AB Science 79
4.6 Heat Map and Competitor Matrix for Pipeline Products 81
5 Market Forecast to 2020 84
5.1 Geographical Markets 84
5.2 Global Market 85
5.3 North America 88
5.3.1 Treatment Usage Patterns 88
5.3.2 Annual Cost of Therapy 90
5.3.3 Market Size 92
5.4 Top Five Countries of Europe 94
5.4.1 Treatment Usage Patterns 94
5.4.2 Annual Cost of Therapy 95
5.4.3 Market Size 97
5.5 Japan 98
5.5.1 Treatment Usage Patterns 98
5.5.2 Annual Cost of Therapy 98
5.5.3 Market Size 99
5.6 Drivers and Barriers for the Asthma Market 100
5.6.1 Drivers 100
5.6.2 Barriers 100
6 Strategic Consolidations 102
6.1 Co-development Deals 102
6.1.1 Sepracor Enters into Co-Development Agreement with Nycomed for Ciclesonide 107
6.1.2 NeoStem Enters into Agreement with University of California to Develop Human Regulatory T Cells 108
6.1.3 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 108
6.2 Licensing Deals 108
6.2.1 Amgen Enters into Licensing Agreement with Kyowa Hakko Kirin - Terminated 115
6.2.2 Mundipharma Enters into Licensing Agreement with SkyePharma 116
6.2.3 MAP Pharmaceuticals Enters into Licensing Agreement with AstraZeneca - Terminated 116
6.2.4 Orexo Enters into Licensing Agreement with Janssen Pharmaceuticals - Terminated 116
6.2.5 Aslan Pharma Enters into Licensing Agreement with CSL for CSL-334 117
7 Appendix 118
7.1 All Pipeline Drugs by Phase of Development 118
7.1.1 Discovery 118
7.1.2 Preclinical 119
7.1.3 Phase I 124
7.1.4 Phase II 125
7.1.5 Phase III 127
7.1.6 Pre-registration 128
7.2 Market Forecasts to 2020 128
7.2.1 Global 128
7.2.2 US 129
7.2.3 Canada 129
7.2.4 UK 129
7.2.5 France 130
7.2.6 Germany 130
7.2.7 Italy 130
7.2.8 Spain 131
7.2.9 Japan 131
7.3 References 131
7.4 Abbreviations 137
7.5 Research Methodology 137
7.5.1 Secondary Research 138
7.5.2 Marketed Product Profiles 138
7.5.3 Late-Stage Pipeline Candidates 139
7.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 139
7.5.5 Product Competitiveness Framework 139
7.5.6 Pipeline Analysis 139
7.5.7 Forecasting Model 140
7.5.8 Deals Data Analysis 141
7.6 Expert Panel Validation 141
7.7 Contact Us 142
7.8 Disclaimer 142

Request Discount at:- https://marketreportscenter.com/request-discount/5228

About Us:

Market Reports Center is an e-commerce platform obliging the needs of knowledge workers, experts, professionals who are subject to market research information for their work, or to make strategic business decisions. Market Reports Center’s team consistently works to update and extend our existing repository of market research reports by partnering with new publishers and adding their studies to our website.

Contact Us:

Call:  +1-646-883-3044 (US)

Mail:  info@marketreportscenter.com

Follow us:

Twitter: https://twitter.com/reports_market

Facebook: https://www.facebook.com/marketreportscenter

LinkedIn: https://www.linkedin.com/company/market-reports-center